[Neurogenic inflammation. II. pathophysiology and clinical implications].
Neurogenic inflammation is elicited by activation of unmyelinated sensory neurons through noxious stimuli and subsequent release of neuropeptides such as substance P and calcitonin gene-related peptide (CGRP) from peripheral nerve endings. The nerve-mediated inflammatory responses in the tissue consist of hyperaemia and oedema which under some circumstances may be accompanied by pain. Neurogenic inflammation has been implicated in the pathophysiology of various human diseases with uncertain etiology. Signs of inflammation and hyperalgesia associated with chronic pain syndromes such as migraine, arthritis and complex regional pain syndrome resemble the characteristics of neurogenic inflammation. By extrapolation of convincing evidence obtained in rodent models, neurogenic inflammation is assumed to contribute to diseases of the respiratory system, gastrointestinal tract, urogenital tract, and skin in humans. Since, however, highly selective substance P receptor antagonists, found to be effective against inflammation in rodents, failed to inhibit inflammatory processes in clinical trials, the hypothesis of an involvement of neurogenic inflammation in human diseases is discussed critically in this review. Beyond its primarily inflammatory character neurogenic inflammation can be regarded as a mechanism that activates protective responses, thus bringing about a first line of defence to maintain the integrity of the tissue and to contribute to tissue repair.
Herbert
M K
MK
Klinik für Anaesthesiologie, Universität Würzburg. mherbert@anaesthesie.uni-wuerzburg.de
Holzer
P
P
D000818:Animals; D002908:Chronic Disease; D006801:Humans; D009475:Neurons, Afferent / Q000473:pathology; D009479:Neuropeptides / Q000037:antagonists & inhibitors / Q000502:physiology; D010146:Pain / Q000209:etiology / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy*
D009479:Neuropeptides